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OBJECTIVE—Heat shock protein 27 (HSP27) is a member of
the small heat shock protein family of proteins. HSP27 expres-
sion is enhanced in target tissues of diabetic microvascular
complications, and changes in circulating serum HSP27 levels
(sHSP27) have been reported in patients with macrovascular
disease. We investigated whether sHSP27 levels were associated
with micro- and macrovascular complications in type 1 diabetic
patients.
RESEARCH DESIGN AND METHODS—A cross-sectional,
nested, case-control study from the EURODIAB Prospective
Complications Study of 531 type 1 diabetic patients was per-
formed. Case subjects (n  363) were deﬁned as those with one
or more complications of diabetes; control subjects (n  168)
were deﬁned as those with no evidence of any complication. We
measured sHSP27 levels and investigated their associations with
diabetes complications.
RESULTS—Mean sHSP27 levels were signiﬁcantly higher in
case subjects with distal symmetrical polyneuropathy (DSP) than
in control subjects, even after adjustment for age and albumin
excretion rate (AER) (785.9 vs. 574.7 pg/ml, P  0.03). In logistic
regression analysis, sHSP27 levels in the upper quartile were
associated with a twofold increased odds ratio (OR) of DSP,
independently of conventional risk factors, markers of inﬂamma-
tion, and AER (OR 2.41 [95% CI 1.11–5.24]).
CONCLUSIONS—In this large cohort of type 1 diabetic sub-
jects, we found an independent association between sHSP27 and
DSP. This suggests that sHSP27 levels may be a novel marker for
diabetic neuropathy. Diabetes 57:1966–1970, 2008
H
eat shock protein 27 (HSP27), a member of the
small heat shock protein family of proteins, is a
highly conserved peptide of 27 kDa associ-
ated with cytoskeletal actin (1). In addition to
its chaperone activity, HSP27 acts as a ﬁlament stabilizer
under stress conditions, interferes with apoptotic path-
ways, and participates in cytoskeletal dynamics by con-
trolling actin polymerization (2). Therefore, HSP27 plays
an important role in both cytoprotection and cell motility.
Recent studies in experimental diabetes have shown
HSP27 overexpression in glomeruli (3), dorsal root ganglia
(4,5), retina (6), and the area adjacent to atherosclerotic
plaque (7), indicating HSP27 induction in target tissues of
diabetes complications. HSP27 is also released into circu-
lation (8). A pilot study has shown reduced plasma HSP27
levels in patients with carotid stenosis (9), but in a more
recent study, HSP27 levels were increased in patients with
acute coronary syndromes (7). However, no large study is
yet available on circulating HSP27 in vascular disease.
Type 1 diabetes is associated with a greatly increased
risk of vascular complications that cannot be completely
accounted for by conventional risk factors. The aim of the
present study was to assess whether high serum HSP27
(sHSP27) levels increased odds ratios (ORs) of micro- and
macrovascular complications in a nested case-control
sample of type 1 diabetic individuals from the EURODIAB
Prospective Complications Study.
RESEARCH DESIGN AND METHODS
The EURODIAB Prospective Complications Study (1997–1999) is a follow-up
of the EURODIAB Type 1 Diabetes Complications Study (1989–1991), which
was designed to explore risk factors for diabetes complications in 3,250
randomly selected people with type 1 diabetes, aged 15–60 years, attending 31
diabetes centers in 16 European countries (10,11).
A cross-sectional, nested, case-control study was designed at the 1997–1999
follow-up examination (12–15). The response rate at follow-up examination was
57.8% (16). Case subjects were selected based on the greatest complication
burden possible in order to provide sufﬁcient numbers for subgroup analyses.
Thus, case subjects were deﬁned as those with cardiovascular disease,
proliferative retinopathy, or micro- or macroalbuminuria at follow-up. Control
subjects were selected based on being completely free of complications. This
design allowed the comparison of individuals with single or multiple compli-
cations with individuals free of complications, according to the study ques-
tion, as efﬁciently as possible. Applying these criteria, this yielded 363 case
and 168 control subjects with full data on complications and samples available
for analysis. The sample size provides a power of 95 and 80% (0.05),
respectively, to detect a difference in log-HSP27 of at least one-third of an SD
between all case and control subjects and between case subjects with single
complications and control subjects with no complications.
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1966 DIABETES, VOL. 57, JULY 2008Patient evaluation for the presence of cardiovascular risk factors (hyper-
tension, BMI, waist-to-hip ratio, smoking, cholesterol, triglycerides, and A1C)
is described elsewhere (12–15). Retinopathy was graded according to the
EURODIAB protocol (17). Albumin excretion rate (AER), assessed on two
24-h urine collections by the immunoturbidimetric method, was categorized
as normoalbuminuria (20 g/min), microalbuminuria (20–200 g/min), and
macroalbuminuria (200 g/min). Cardiovascular disease (CVD) was deﬁned
as physician-diagnosed myocardial infarction, angina, coronary artery bypass
graft, or stroke and/or ischemic changes on a centrally Minnesota-coded
electrocardiogram. Distal symmetrical polyneuropathy (DSP) was diagnosed
on the basis of 1) the presence of one or more neuropathic symptoms, 2) the
absence of two or more ankle or knee reﬂexes, and 3) abnormal vibration
perception threshold, measured by centrally calibrated biothesiometers (Bio-
medical, Newbury, OH) on the right big toe and on the right medial malleolus.
Soluble vascular cell adhesion molecule (sVCAM)-1, soluble E-selectin
(sE-selectin), interleukin (IL)-6, and tumor necrosis factor (TNF)- were
measured by commercially available enzyme-linked immunosorbent assay
(ELISA) (R&D Systems, Oxon, U.K.), and plasma levels of C-reactive protein
(CRP) and Amadori albumin were measure by in-house ELISA (12,13). Plasma
homocysteine was determined with an automated ﬂuorescence polarization
immunoassay on an Abbott IMx analyzer (Abbott Laboratories, Abbott Park,
IL) (18). sHSP27 levels were measured by ELISA (Calbiochem, San Diego,
CA). Brieﬂy, 96-well plates were precoated with a mouse anti-human HSP27,
used as capture antibody. Then, both HSP27 standards and samples, together
with a rabbit polyclonal detection antibody speciﬁc for human HSP27, were
simultaneously incubated in the precoated wells. After washing, a goat
anti-rabbit IgG conjugated to horseradish peroxidase was added. Reaction
was revealed by 3,3,5,5-tetramethylbenzidine dihydrochloride substrate and
stopped with sulfuric acid. The absorbance was read at 450 nm, and HSP27
levels were determined by comparing the absorbance of samples with the
values obtained from the standard curve. The range of the assay was 20–1,000
pg/ml and intra- and interassay CVs were 4.4 and 8.5–9%, respectively, for both
low (132 pg/ml) and high (993 pg/ml) range HSP27 levels. Samples were coded
and tested blind.
Statistical analyses. Variables distributed normally are presented as
means  SD, whereas variables with skewed distribution were analyzed after
logarithmic transformation (triglycerides, AER, creatinine, CRP, IL-6, TNF-,
sVCAM, sE-selectin, homocysteine, HSP27) and are presented as geometric
means (interquartile range). Logistic regression analyses were used to esti-
mate the ORs of HSP27 for any complication (AER 20 g/min, retinopathy,
neuropathy, CVD), independently of confounders and known risk factors.
Both backward and forward strategies examining all explanatory variables
were used to select models. The likelihood ratio test was used to compare
nested models examining the role of age, sex, diabetes duration, BMI,
waist-to-hip ratio, A1C, blood pressure, lipids, AER, CRP, IL-6, TNF-, homocys-
teine, Amadori albumin, sE-selectin, sVCAM, and smoking. Analyses were hypoth-
esis oriented and did not use stepwise regression (19). Variables were retained in
the ﬁnal model if they added signiﬁcantly to the likelihood of models or to the
estimated coefﬁcients of predictors. In light of the hypothesis of a different role of
HSP27 in the pathogenesis of different complications, logistic regression models
were also ﬁtted separately for each complication. To assess patterns of ORs
across increasing HSP27 values, ORs were categorized by the quartile distribution
in control subjects. We tested for linear trends across quartiles by entering a
single ordinal term into the models. When ORs in the lower quartiles of HSP27
were similar, they were aggregated as the reference category in the ﬁnal analysis
and compared with the upper quartile.
RESULTS
The study population (n  531) had a mean age of 39.6
years, a mean diabetes duration of 21.5 years, and an equal
proportion of men and women. Case subjects with vascu-
lar complications had a more adverse risk factor proﬁle
than control subjects (Table 1). Of the 363 case subjects,
nephropathy was present in 206 (22.6% micro- and 34.3%
macroalbuminuria), retinopathy in 292 (background 39.1%
and proliferative 41.3%), DSP in 205 (56.5%), and auto-
nomic neuropathy in 118 (27.6%). Most people, however,
had more than one complication; indeed, 187 (51.5%)
individuals had both AER 20 g/min and retinopathy,
128 (35.3%) had both AER 20 g/min and DSP, and 123
(33.9%) had AER 20 g/min, DSP, and retinopathy. CVD
was present in 146 subjects (40.2%), all of whom also had
at least one microvascular complication, apart from 12
individuals who had CVD only.
HSP27 was measurable in all 531 samples, with a
right-skewed distribution of values (Table 1). sHSP27
levels were not signiﬁcantly different in case and control
subjects, even after adjustment for age (670.9 vs. 548.8
pg/ml, P  0.08). With respect to control subjects, how-
ever, we found signiﬁcantly greater age-adjusted HSP27
levels in case subjects with DSP (P  0.002) and in case
subjects with micro-/macroalbuminuria (P  0.03). Al-
though sHSP27 levels were also slightly higher in case
TABLE 1
Baseline characteristics of the 531 subjects with type 1 diabetes of the EURODIAB Prospective Complications Study
Case subjects Control subjects P
n 363 168
Age (years) 41.4  10.5 35.7  7.7 0.0001
Diabetes duration (years) 24.4  9.3 15.4  6.7 0.0001
Males (%) 52.3 48.8 0.45
BMI (kg/m
2) 24.9  3.5 23.6  2.5 0.0001
Waist-to-hip ratio 0.89  0.12 0.89  0.17 0.64
A1C (%) 8.9  1.6 7.7  1.2 0.0001
Systolic blood pressure (mmHg) 127.0  21.7 114.9  13.1 0.0001
Diastolic blood pressure (mmHg) 75.8  11.7 73.7  10.6 0.04
Hypertension (%) 54.6 13.8 0.0001
Total cholesterol (mmol/l) 5.46  1.18 4.91  1.08 0.0001
LDL cholesterol (mmol/l) 3.60  1.11 3.06  0.97 0.0001
HDL cholesterol (mmol/l) 1.61  0.44 1.67  0.42 0.14
Triglycerides (mmol/l) 1.21 (0.83–1.58) 0.84 (0.66–1.09) 0.0001
AER (g/min) 51.0 (7.3–347.6) 6.4 (4.5–9.2) 0.0001
CRP (mg/l) 1.23 (0.52–2.88) 0.75 (0.36–1.69) 0.0001
IL-6 (pg/ml) 2.48 (1.34–3.91) 1.71 (1.06–2.50) 0.0001
TNF- (pg/ml) 3.22 (2.34–4.29) 2.14 (1.67–2.78) 0.0001
Homocysteine (mol/l) 7.7 (5.7–9.6) 6.8 (5.6–81) 0.002
Amadori albumin (U/ml) 47.0  13.5 42.2  12.3 0.0001
E-selectin (ng/ml) 33 (26–44) 29 (22–38) 0.0001
sVCAM (ng/ml) 412 (340–500) 368 (516–420) 0.0001
HSP27 (pg/ml) 658.0 (286.4–1,315.0) 567.6 (250.0–1,136.0) 0.18
Data are means  SD, percentage, or geometric means (25th–75th centile) for log-transformed data.
G. GRUDEN AND ASSOCIATES
DIABETES, VOL. 57, JULY 2008 1967subjects with retinopathy (P  0.06), this was mainly due
to the confounding association with AER, as values be-
came similar after further adjustment for AER (P  0.57).
On the contrary, the difference between case subjects with
DSP and control subjects was signiﬁcant, even after fur-
ther adjustment for AER (785.9 vs. 574.7 pg/ml, P  0.03).
No difference was found between case subjects with CVD
and control subjects.
We then performed logistic regression analyses to as-
sess whether higher values of HSP27 conferred an increased
OR of having any complication, independently of main risk
factors. Models performed in all subjects and separately for
each complication showed a tendency toward a negative
confounding effect of both age and diabetes duration (in-
creasing ORs from model 1 to model 2) and a positive
confounding effect of A1C, hypertension, smoking, and
TNF-(decreasing ORs from model 2 to model 3). In the fully
adjusted model, a signiﬁcant linear trend of ORs across
quartiles of HSP27 was evident for DSP (P  0.03), whereas
a signiﬁcant linear trend for micro-/macroalbuminuria and
retinopathy was present exclusively in the age- and duration-
adjusted model (model 2) (Table 2).
HSP27 values in the upper quartile (1,135 pg/ml)
conferred a 38% increased OR (95% CI 0.77–2.49) of any
complications compared with HSP27 values in the lower
quartiles (1,135 pg/ml). Final models, performed sepa-
rately for each complication, showed that higher HSP27
values were associated with a more than twofold in-
creased OR of DSP, which was statistically signiﬁcant (OR
2.45 [95% CI 1.20–5.03]), even after further adjustment for
AER values (2.41 [1.11–5.24]). ORs for other complications
were increased in the upper versus lowers quartiles, but
they did not reach statistical signiﬁcance (Table 2). Study
center did not contribute signiﬁcantly to the ﬁnal model
and did not modify estimated ORs.
DISCUSSION
In this cross-sectional sample of type 1 diabetic patients
from the EURODIAB Prospective Complications Study,
TABLE 2
OR (95% CI) values for diabetes complications by HSP27 values in the nested case-control study within the EURODIAB Prospective
Complications Study
OR (95% CI) OR (95% CI)* OR (95% CI)†
All complications
logHSP27 1.11 (0.95–1.31) 1.14 (0.95–1.36) 1.15 (0.93–1.43)
HSP27 (pg/ml)
250.0 1.00 1.00 1.00
250.0–507.1 1.22 (0.72–2.07) 1.22 (0.66–2.23) 0.94 (0.45–1.97)
507.2–1,135.0 1.13 (0.67–1.92) 1.42 (0.78–2.60) 0.92 (0.44–1.95)
1,135.0 1.42 (0.85–2.39) 1.55 (0.85–2.82) 1.31 (0.64–2.73)
P for trend 0.24 0.13 0.47
DSP
logHSP27 1.24 (1.04–1.49) 1.32 (1.06–1.63) 1.53 (1.16–2.02)
HSP27 (pg/ml)
250.0 1.00 1.00 1.00
250.0–507.1 1.36 (0.74–2.50) 1.13 (0.54–2.39) 0.65 (0.24–1.74)
507.2–1,135.0 1.39 (0.76–2.54) 1.84 (0.89–3.82) 1.19 (0.46–3.10)
1,135.0 1.94 (1.08–3.50) 2.13 (1.04–4.33) 2.27 (0.90–5.75)
P for trend 0.03 0.016 0.03
Micro-/macroalbuminuria
logHSP27 1.19 (1.00–1.42) 1.21 (0.98–1.41) 1.24 (0.92–1.68)
HSP27 (pg/ml)
250.0 1.00 1.00 1.00
250.0–507.1 1.20 (0.66–2.18) 1.22 (0.58–2.55) 0.88 (0.31–2.52)
507.2–1,135.0 1.31 (0.72–2.37) 2.10 (1.02–4.32) 1.10 (0.38–3.16)
1,135.0 1.68 (0.94–2.99) 1.92 (0.95–3.89) 1.56 (0.58–4.20)
P for trend 0.08 0.03 0.31
Retinopathy
logHSP27 1.13 (0.96–1.34) 1.15 (0.94–1.41) 1.16 (0.90–1.51)
HSP27 (pg/ml)
250.0 1.00 1.00 1.00
250.0–507.1 1.15 (0.66–1.99) 1.21 (0.61–2.40) 0.98 (0.41–2.38)
507.2–1,135.0 1.23 (0.71–2.13) 1.94 (0.99–3.82) 1.35 (0.55–3.29)
1,135.0 1.48 (0.87–2.54) 1.69 (0.86–3.31) 1.39 (0.58–3.34)
P for trend 0.15 0.06 0.34
CVD
logHSP27 1.13 (0.93–1.37) 1.18 (0.94–1.49) 1.10 (0.83–1.46)
HSP27 (pg/ml)
250.0 1.00 1.00 1.00
250.0–507.1 1.43 (0.75–2.72) 1.86 (0.84–4.14) 1.22 (0.47–3.15)
507.2–1,135.0 1.25 (0.65–2.41) 1.83 (0.82–4.08) 1.09 (0.41–2.86)
1,135.0 1.54 (0.81–2.91) 1.91 (0.86–4.24) 1.23 (0.48–3.16)
P for trend 0.28 0.16 0.74
*Adjusted for age and diabetes duration. †Adjusted for age, diabetes duration, hypertension, A1C, smoking, and logTNF-.
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association between sHSP27 levels and DSP. Mean
sHSP27 levels were signiﬁcantly higher in case subjects
with DSP than in control subjects, even after adjustment
for age and AER. Furthermore, in logistic regression
analysis, higher circulating HSP27 levels conferred a two-
fold increased OR of DSP, independently of conventional
risk factors, markers of inﬂammation, and AER. The lack
of circulating markers for DSP represents an important
limit of clinical research in this ﬁeld; therefore, our ﬁnd-
ings may be of potential clinical relevance. Availability of
a surrogate marker of DSP, which can be easily and
noninvasively obtained, may facilitate diagnosis, measure-
ment of progression, and assessment of therapeutic
interventions.
The rise in circulating HSP27 expression in patients with
DSP may result from neuronal overexpression. Consistent
with this hypothesis, studies in experimental diabetes
have shown HSP27 induction in the sensory neurons of the
dorsal root ganglia (4,5). Intracellular HSP27, a key sur-
vival factor for neurons, plays an important role in axonal
regeneration (20), and mutations of the HSPB1 gene
encoding for HSP27 cause inherited distal peripheral neu-
ropathies, such as hereditary distal motor neuropathy and
Charcot-Marie-Tooth disease type 2 (21). The mechanism
of HSP27 neuroprotection is unclear, but preservation of
the cytoskeletal stability and both chaperone-like and
anti-apoptotic activities have been implicated (22). In
diabetic patients with DSP, overexpression of HSP27 may
thus be aimed to counteract the neurological damage
caused by the diabetic milieu. On the other hand, HSP27
release can also contribute to the neuronal damage, as
anti-HSP27 autoantibodies, which are produced in re-
sponse to extracellular HSP27 exposure, can induce neu-
ronal apoptosis (23).
There are certain limitations to our study. First, this is a
cross-sectional study, hence restricting our ability to as-
sess temporal relationships between sHSP27 levels and
microvascular complications and to identify causal biolog-
ical mechanisms underlying this association. However, no
data on HSP27 in large groups of type 1 diabetic patients
exist; therefore, this study may serve as a reasonable
starting point to explore the role of this molecule in type 1
diabetes. Second, the number of control subjects was
lower than the overall number of case subjects, thus
reducing the power of analyses; comparisons between
control subjects and case subjects with single complica-
tions allowed a more favorable case-to-control ratio, but
multiple comparisons within the same case-control study
base might have caused signiﬁcant results due to chance.
Third, although serum samples were adequately stored,
the possibility of protein degradation cannot be excluded;
however, random misclassiﬁcation would have biased our
estimates downward, without affecting signiﬁcant associ-
ations. Unlike previous studies, a key strength here is the
ability to account for confounding by other risk factors
and complications, and the large sample size provides
sufﬁcient power for these analyses. In addition, our pa-
tients were from a representative sample of people with
type 1 diabetes across Europe, and our results are there-
fore likely to be generalizable.
In conclusion, this is the ﬁrst study measuring sHSP27 in
a large group of subjects, and the results provide evidence
that sHSP27 levels are independently associated with DSP
in type 1 diabetic patients. Further studies are required to
determine causal relationships and elucidate underlying
mechanisms.
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